for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cipla Ltd

CIPL.NS

Latest Trade

971.90INR

Change

-7.70(-0.79%)

Volume

7,193,857

Today's Range

969.15

 - 

997.00

52 Week Range

621.05

 - 

997.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
979.60
Open
992.20
Volume
7,193,857
3M AVG Volume
129.84
Today's High
997.00
Today's Low
969.15
52 Week High
997.00
52 Week Low
621.05
Shares Out (MIL)
806.60
Market Cap (MIL)
790,142.20
Forward P/E
28.91
Dividend (Yield %)
0.31

Next Event

Q1 2022 Cipla Ltd Earnings Release

Latest Developments

More

Dr Reddy's, Cipla, Emcure, Sun Pharma And Torrent To Partner For Clinical Trial Of Molnupiravir For COVID-19

Cipla Gets Final Approval For Generic Version Of Sunovion Pharmaceuticals' Brovana

Cipla Says Roche's Antibody Cocktail (Casirivimab & Imdevimab) Now Available In India

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cipla Ltd

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.

Industry

Biotechnology & Drugs

Contact Info

Mumbai Central

400013

India

+91.22.24826000

https://www.cipla.com/

Executive Leadership

Yusuf K. Hamied

Non-Executive Chairman of the Board

Umang Vohra

Global Chief Executive Officer, Managing Director, Executive Director

Samina Hamied

Executive Vice Chairman of the Board

M. K. Hamied

Non-Executive Vice Chairman of the Board

Kedar Upadhye

Global Chief Financial Officer

Key Stats

1.75 mean rating - 36 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2019

163.6K

2020

171.3K

2021

189.9K

2022(E)

210.7K
EPS (INR)

2019

18.930

2020

19.160

2021

29.790

2022(E)

33.884
Price To Earnings (TTM)
32.89
Price To Sales (TTM)
4.12
Price To Book (MRQ)
4.31
Price To Cash Flow (TTM)
22.78
Total Debt To Equity (MRQ)
8.39
LT Debt To Equity (MRQ)
6.56
Return on Investment (TTM)
12.23
Return on Equity (TTM)
9.84

Latest News

Latest News

India's Cipla gets nod to distribute partner Moderna's COVID vaccine

Indian drugmaker Cipla Ltd has received regulatory approval to distribute partner Moderna Inc's COVID-19 vaccine in the country, a senior government official said on Tuesday, clearing the way for the shot to be imported.

India grants emergency approval for Moderna's COVID-19 vaccine - govt official

India's Cipla Ltd has been granted a new drug permission for restricted use of Moderna Inc's COVID-19 vaccine in the country, a senior government official said on Tuesday.

India's Cipla to make and sell Eli Lilly's baricitinib to treat COVID-19

Indian drugmaker Cipla Ltd said on Monday it has entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly's arthritis drug baricitinib for the treatment of COVID-19 patients. (Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Rashmi...

Cipla doubles remdesivir production to meet 'unprecedented' demand

India's Cipla Ltd has doubled production of COVID-19 medication remdesivir to help meet "unprecedented demand" as the country battles a massive second wave of infections, the drugmaker said on Tuesday.

Sensex, Nifty end higher; Burger King more than doubles in market debut

Indian shares ended higher on Monday after scaling record peaks earlier in the session, with Burger King India soaring more than 100% in its market debut and gains in drugmaker Cipla helping boost the Nifty.

Indian demand for COVID-19 drug remdesivir rising sharply - Cipla

Demand for COVID-19 antiviral drug remdesivir is rising sharply in India, a top executive at drugmaker Cipla Ltd <CIPL.NS> said on Monday, even as experts remain divided over its effectiveness.

India's shortage of remdesivir is easing, says producer Cipla

India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd.

Cipla gets India approval to sell COVID-19 drug favipiravir

Cipla Ltd has received Indian regulatory approval to sell anti-viral drug favipiravir to treat COVID-19, the drugmaker said on Friday, as coronavirus infections in the world's third worst-hit nation show no sign of abating.

India's Cipla prices its generic remdesivir at $53.34 per vial, below rivals

Cipla Ltd has priced its generic version of remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, the Indian drugmaker said on Wednesday, making it among the lowest priced versions of the COVID-19 treatment available so far globally.

India's Cipla set to undercut rivals with generic remdesivir -sources

Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally.

BRIEF-Cipla Commercially Launches Generic Version Of Remdesivir

* CIPLA LTD SAYS COMMERCIALLY LAUNCHES CIPREMI (REMDESIVIR) ON WEDNESDAY -STATEMENT

India's Sovereign Pharma dispatches first batch of remdesivir to Cipla

India's Sovereign Pharma said it has dispatched the first batch of generic remdesivir for drugmaker Cipla Ltd, as the country recorded more than 22,000 new coronavirus cases on Tuesday.

India's Cipla to price remdesivir version for COVID-19 under $66

Indian drugmaker Cipla Ltd will price its generic version of Gilead Sciences Inc's antiviral drug remdesivir for use in COVID-19 patients at less than 5,000 rupees ($66), the company said.

India gives Hetero Labs and Cipla approval to make Gilead's COVID-19 drug

India's drug regulator has given Hetero Labs and Cipla Ltd <CIPL.NS> the green light to manufacture and market their generic version of Gilead Sciences Inc's <GILD.O> experimental COVID-19 treatment remdesivir, the Indian pharmaceutical companies said on Sunday.

BRIEF-Cipla Signs Pact With Roche Products (India) Pvt. Ltd

* SIGNS DISTRIBUTION AGREEMENT WITH ROCHE PRODUCTS (INDIA) PVT. LTD

India's Zydus Cadila to make Gilead's potential COVID-19 drug remdesivir

Indian drugmaker Zydus Cadila said on Friday it signed a non-exclusive licensing pact with Gilead Sciences Inc to manufacture and market antiviral drug remdesivir, the first treatment to show improvement in COVID-19 trials.

BRIEF-Cipla Ltd -Gets Final Approval For Generic Version Of Migranal

* CIPLA LTD -RECEIVES FINAL APPROVAL FOR GENERIC VERSION OF MIGRANAL® (DIHYDROERGOTAMINE MESYLATE NASAL SPRAY 4MG/ML) Source text for Eikon: Further company coverage:

Indian shares fall as economic package fails to impress; Reliance rises

Indian shares slipped on Monday as investors were unimpressed by the government's economic relief measures and coronavirus cases continued to rise steadily, while a boost in Reliance Industries and Cipla limited losses.

BRIEF-Cipla Files ANDA For Generic Version Of GSK's Advair Diskus

* CIPLA FILES ANDA FOR GENERIC VERSION OF GSK'S ADVAIR DISKUS Source text for Eikon: Further company coverage:

BRIEF-Cipla Ltd - Approved Raising Of Funds Of Upto 30 Billion Rupees

* CIPLA LTD - APPROVED RAISING OF FUNDS OF UPTO 30 BILLION RUPEES Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up